ABO incompatible kidney transplantation

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 6, 2007, Pages 529-534

  Gloor, James M ^a,b   Stegall, Mark D ^b  

^a Division of Nephrology and Hypertension   (United States)

^b MAYO CLINIC   (United States)

Author keywords

ABO incompatible; Kidney transplantation

Indexed keywords

CD4 ANTIGEN;

ANTIBODY TITER; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP B; COST EFFECTIVENESS ANALYSIS; DONOR; GLOMERULOPATHY; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE UTILIZATION; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HUMORAL IMMUNITY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE PRESSURE; LONG TERM CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SURGICAL RISK; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; COMPLEMENT C4B; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS;

EID: 37349130254     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f02218     Document Type: Review

References (56)

1. Tanabe K, Tokumoto T, Ishida H, et al. ABO-incompatible renal transplantation at Tokyo Women's Medical University. In: Cecka JM, Terasaki PI, editors. Clinical transplants 2003. Los Angeles: UCLA Immunogenetics Center; 2003. pp. 175-181.
2. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971-977.
3. Alexandre GPJ, Latinne D, Carlier M, et al. ABO-incompatibility and organ transplantation. Transplantation Reviews 1991; 5:230-241.
4. Ivanovski N, Popov Z, Masin-Spasovska J, et al. First two ABO-incompatible living renal transplantations using splenectomy, rituximab, plasmapheresis and IVIG as a preconditioning regimen: a single center experience in the Balkans. Xenotransplantation 2006; 13:123-125.
5. Tyden G, Kumlien G, Genberg H, et al. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplantation 2006; 13:105-107.
6. Ahlenstiel T, Offner G, Strehlau J, et al. ABO-incompatible kidney transplantation of an 8-yr-old girl with donor/recipient constellation A1B/B. Xenotransplantation 2006; 13:141-147.
7. Bannett AD, McAlack RF, Raja R, et al. Experiences with known ABO-mismatched renal transplants. Transplant Proc 1987; 19:4543-4546.
8. Donauer J, Wilpert J, Geyer M, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation 2006; 13:108-110.
9. Kayler LK, Colombe B, Farber JL, et al. Successful living donor renal transplantation despite ABO incompatibility and a positive crossmatch. Clin Transplant 2004; 18:737-742.
10. Mannami M, Mitsuhata N. Improved outcomes after ABO-incompatible donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation 2005; 79:1756-1758.
11. Norden G, Briggs D, Cockwell P, et al. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation 2006; 13:148-153.
12. Saito K, Nakagawa Y, Suwa M, et al. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006; 13:111-117.
13. Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and DFPPenabled nonresponders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18:254-260.
14. Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplantation 2005; 9:148-154.
15. Takahashi K, Saito K, Shiro T, et al. Excellent long-term outcome of ABOincompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089-1096.
16. Takahashi K, Saito K. Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006; 13:118-122.
17. Starzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964; 55:195-200.
18. Cook DJ, Graver B, Terasaki PI. ABO incompatibility in cadaver donor kidney allografts. Transplant Proc 1987; 19:4549-4552.
19. Slapak M, Digard N, Ahmed M, et al. Renal transplantation across the ABO barrier: a 9-year experience. Transplant Proc 1990; 22:1425-1428.
20. Futagawa Y, Terasaki PI. ABO incompatible kidney transplantation: an analysis of UNOS registry data. Clin Transplant 2005; 20:122-126.
21. Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70:1331-1335.
22. Shimmura H, Tanabe K, Ishida H, et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005; 80:985-988.
23. Alexandre GPJ, Squifflet JP, De Bruyere M, et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 1985; 17:138-143.
24. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315-1322.
25. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145-148.
26. Segev DL, Simpkins CE, Warren A, et al. ABO incompatible high titer renal transplantation without splenectomy or anti-CD20 antibody. Am J Transplant 2005; 5:2570-2575.
27. Gloor JM, Lager DJ, Fidler ME, et al. A comparison of splenectomy vs. intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572-1577.
28. Breimer ME, Molne J, Norden G, et al. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and Secretor status. Transplantation 2006; 82:479-485.
29. Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67:1319-1324.
30. Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001; 1:296-299.
31. Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantaton 1998; 65:256-269.
32. Nelson PW, Helling TS, Pierce GE, et al. Successful transplantation of blood group A2 kidneys into non-A recipients. Transplantation 1988; 45:316-319.
33. Nelson PW, Aeder MI, Beck ML, et al. An association of anti-A titer in ESRD patients with clinical outcome in transplantation of blood group A2 kidneys into B and O recipients. Human Immunol 1991; 32:55.
34. Table 5.2 Time to transplant, 1996 to 2005: New Kidney Waiting List Registrations. 2006 OPTN/SRTR Annual Report [online resource]; 2006. www.ustransplant.org/annual_Reports/current/502_abo_ki.htm. [Accessed 1 June 2007].
35. Williams WW, Cherikh WS, Young CJ, et al. Updated report on the OPTN/UNOS national voluntary variance to allocate A2/A2B deceased donor kidneys to blood group B candidates [abstract]. Am J Transplant 2006; 6 (Suppl 2):1058.
36. Bryan CF, Nelson PW, Shield CF, et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. Am J Transplant 2007; 7:1-4. This investigation of A2 incompatible transplants showed that long-term outcome is similar to that seen in ABOC transplants.
37. Schnuelle P, van der Woude FJ. Should A2 kidneys be transplanted into B or O recipients? Lancet 1998; 351:1675-1676.
38. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65:224-228.
39. Bryan CF, McDonald SB, Harrell KM, et al. A method comparison for performing the anti-A titer assay for transplantation of A2 kidneys into B and O patients. Transplantation 2000; 96:s339.
40. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaan addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
41. Bohmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7:117-121. This article provides support for the use of plasmapheresis or immunoadsorption in the therapy of acute humoral rejection, and illustrates the inadequacy of therapy directed only against acute cellular rejection.
42. Fidler ME, Gloor JM, Lager DJ, et al. Histologic findings of antibody-mediated rejection in ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2004; 4:101-107.
43. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO-and HLA incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829-1840. C4d deposition in ABOI transplants is common in the absence of other histologic abnormalities or allograft dysfunction, and C4d deposition alone is insufficient to diagnose acute humoral rejection.
44. Sis B, Kaplan B, Halloran PF. Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accommodation or chronic allograft injury? Am J Transplant 2006; 6:1753-1754.
45. Gloor JM, Cosio FG, Rea D, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6:1841-1847. This investigation documents the long-term implications of acute humoral rejection, showing a high incidence of transplant glomerulopathy on 1-year posttransplant protocol biopsies in patients with prior humoral rejection. In the absence of prior rejection, however, allograft histology is no different from that of ABOC allografts.
46. Cosio FG, Grande J, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5:1-9.
47. Ishida H, Tanabe K, Ishizuka T, et al. Differences in humoral immunity between a nonrejection group and a rejection group after ABO-incompatible renal transplantation. Transplantation 2006; 81:665-671. B lymphocyte populations in peripheral blood and antidonor blood group IgG subclasses in ABOI transplant recipients with prior acute humoral rejection are different from nonrejectors.
48. Mond JJ, Vos Q, Lees A, Snapper C. T cell independent antigens. Curr Opin Immunol 1995; 7:349-354.
49. Herzenberg LA. B-1 cells: the lineage question revisited. Immunologic Reviews 2000; 175:9-22.
50. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635-640.
51. Schwartz J, Stegall MD, Kremers WK, Gloor JM. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. Transplantation 2006; 82:155-163. Although ABOI is more expensive than ABOC transplantation, it is cost effective when compared with the expenses associated with maintenance dialysis.
52. Tyden G. Cost effectiveness of ABO-incompatible kidney transplantations. Transplantation 2006; 82:166. Similar to approaches using plasmapheresis, ABOI using immunoadsorption of antidonor blood group antibodies is also cost effective.
53. Strauss RG, McLeod BC. Complications of therapeutic apheresis. In: Popovsky MA, editor. Transfusion reactions. Bethesda: AABB Press; 1996 . pp. 281-300.
54. Schnitzler M, Machnicki G. ABO-incompatible living donor transplantation: Is it economically 'compatible'? Transplantation 2006; 82:168-169. The authors incorporate an estimate of cost effectiveness of ABOI kidney transplantation taking into account quality of life benefits and show that this approach provides further support for the conclusion that ABOI kidney transplantation is an economically justifiable treatment modality.
55. Whiting J, for the Transplant Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 2000; 70:1115-1121.
56. Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7:518-528.